Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)

NCT05794659 is registered in ClinicalTrials.gov with Aston Sci. Inc. as lead sponsor.

NCT NCT05794659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05794659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)
Lead sponsor
Aston Sci. Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 15, 2023
Completion date
November 15, 2027
Enrollment
98 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ovarian cancer